Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1218-1226

  Prakash, Chandra ^a,b   Johnson, Kim A ^a   Gardner, Mark J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTRIAZOLE DERIVATIVE; CARBON 14; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; FURAFYLLINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; KETOCONAZOLE; LASOFOXIFENE; QUERCETIN; QUINIDINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFAPHENAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TURNOVER TIME; VOLUNTEER;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PYRROLIDINES; REFERENCE VALUES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TANDEM MASS SPECTROMETRY; TETRAHYDRONAPHTHALENES;

EID: 46449112320     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020404     Document Type: Article

References (31)

1. Bollon JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160.
2. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evan DC, et al. (2002) Cylochrome P-450 3A4 mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914.
3. Chlebowski RT, Hendrix SL, Langer RD, Stefaniek ML, Gass M, and Lane D (2003) Influence of estrogen plus progestin on breast cancer and rnammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253.
4. Emons G, Marriam G, Pfeiffer D, Loriaux D, Ball P, and Knuppen R (1987) Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. J Steroid Biochem 28:499-504.
5. Gambacciani M and Ciaponi M (2000) Postmenopausal osteoporosis management. Curr Opin Obstet Gynecol 12:189-197.
6. Gennari L, Merlotti D, Martini G, and Nuti R (2006) Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs 15:1091-1103.
7. Heringa M (2003) Review of raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331-345.
8. Hochner-Celnikier D (1999) Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23-29.
9. Hodis NH, Mack WJ, Azen SP, Lobo RA, Shoupe D, and Mahrer PR (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in poslmenopausal women. N Engl J Med 349:535-545.
10. Johnson K and Prakash C (1998) Identification of in vivo metabolites: characterization of CP-336,156 in cynomolgus monkey by LC/MS/MS. Proceeding of 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, p. 693.
11. Ke HZ, Foley GL, Simmons HA, Shen V, and Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145:1996-2005.
12. Ke HZ, Paralkar VM, Crasser WA, Crawford DT, Qi H. and Simmons HA (1998) Effects of CP-336,156, a new nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139:2068-2076.
13. Lipsett M, Merriam G, Kono S, Brandon D, Pfeiffer D, and Loriaux D (1983) Catechol Estrogens (Merriam G and Lipsett M eds) pp 105-114, Raven Press, New York.
14. Luisetto G, Zangari M, Tizian L, Nardi A, Ramazzina E, and Adami S (1993) Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner 22:9-25.
15. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, and Lasser NL (2003) Estrogen plus progeslin and the risk of coronary heart disease. N Engl J Med 349:523-534.
16. Monks TJ, Hanzlik RP, Cohen GM, Ross D, and Graham DG (1992) Contemporary issues in toxicology: quinone chemistry and toxicity. Toxicol Appl Pharmacol 112:2-16.
17. Morello KC, Wurz GT, and DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361-372.
18. National Institutes of Health Consensus Development Panel on Optimal Calcium Intake (1994) Optimal calcium intake. JAMA 272:1942-1948.
19. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. I. Evidence of its hemoprotein nature. J Biol Chem 239:2370-2378.
20. Ouellet D, Bramson C, Roman D, Remmers AE, Randinitis E, Milton A, and Gardner M (2006) Effect of three cytochrome P40 inhibitors, ketoconazole, fluconazole and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 63:59-66.
21. Prakash C, Kamel A, Cui D, Whalen R, Miceli J, and Tweedie D (2000) Identification of the major human liver eytochrome P450 isoform responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49 (Suppl 1):35S-42S.
22. Prakash C, Shaffer C, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369.
23. Riggs BL, Khosla S, and Melton LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
24. Rosati RL, Da Silva JP, Cameron KO, Thompson DD, Ke HZ, and Toler SM (1998) Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41:2928-2931.
25. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, and Stefanick ML (2002) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Woman's Health Initiative randomized controlled trial. JAMA 288:321-333.
26. Scheline RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523.
27. Snyder KR. Sparano N, and Malinowski JM (2000) Raloxifene hydrochloride. Am J Health Syst Pharm 57:1669-1675.
28. Sowers MR, Finkelstein JS, Ettinger B, Bondarenko I, Neer RM, and Cauley JA (2003a) The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 14:44-52.
29. Sowers MR, Greendale GA, Bondarenko I, Finkelstein JS, Cauley JA, and Neer RM (2003b) Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 14:191-197.
30. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Ann Rev Pharmacol Toxicol 40:581-616.
31. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, and Baird A (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289:2673-2684.